Gene therapy for BAG3-related dilated cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a gene therapy (AFTX-201) for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The therapy aims to improve heart function, and the study will check if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a diagnosed dilated cardiomyopathy and a BAG3 gene mutation.
- Your heart's ejection fraction must be less than 45%.
- You must have symptoms of heart failure (NYHA class II or III).
- You must not have had a heart attack or a heart transplant, and you must not need a heart pump (LVAD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This study follows people with a specific genetic change in the BAG3 gene that causes dilated cardiomyopathy (DCM), a condition where the heart muscle is weakened. It aims to understand the natural course of the disease over time.
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.